Literature DB >> 11068401

[Ataxia-telangiectasia surveyed in Sweden].

A Lähdesmäki1, K Arinbjarnarson, J Arvidsson, M el Segaier, A Fasth, E Fernell, D Gustafsson, V A Oxelius, K Risberg, J Yuen, P Zetterlund, M von Zweigbergk, I Ahsgren, L Hammarström.   

Abstract

Ataxia-telangiectasia (AT) is a rare autosomal recessive disease with a complex phenotype involving cerebellar degeneration, immunodeficiency, cancer risk and radiosensitivity. Our aim has been to identify Swedish AT patients in order to study the possible "Swedish phenotype" of the disease. In the 19 patients identified in Sweden we found a phenotype fairly similar to what has been described internationally, with the exception of some differences including lower cancer incidence in patients and their relatives and somewhat more pronounced immunodeficiency and concomitant susceptibility to infections.

Entities:  

Mesh:

Year:  2000        PMID: 11068401

Source DB:  PubMed          Journal:  Lakartidningen        ISSN: 0023-7205


  4 in total

1.  The impact of an early truncating founder ATM mutation on immunoglobulins, specific antibodies and lymphocyte populations in ataxia-telangiectasia patients and their parents.

Authors:  A Stray-Pedersen; T Jónsson; A Heiberg; C R Lindman; E Widing; I S Aaberge; A L Borresen-Dale; T G Abrahamsen
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

Review 2.  Ataxia-telangiectasia: future prospects.

Authors:  Mohammed Wajid Chaudhary; Raidah Saleem Al-Baradie
Journal:  Appl Clin Genet       Date:  2014-09-10

3.  The ATM signaling network in development and disease.

Authors:  Travis H Stracker; Ignasi Roig; Philip A Knobel; Marko Marjanović
Journal:  Front Genet       Date:  2013-03-25       Impact factor: 4.599

4.  Disparate roles of ATR and ATM in immunoglobulin class switch recombination and somatic hypermutation.

Authors:  Qiang Pan-Hammarström; Aleksi Lähdesmäki; Yaofeng Zhao; Likun Du; Zhihui Zhao; Sicheng Wen; Victor L Ruiz-Perez; Deborah K Dunn-Walters; Judith A Goodship; Lennart Hammarström
Journal:  J Exp Med       Date:  2006-01-03       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.